Investigational drug · Phase 2
AK139
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
7
Any phase or sponsor naming "AK139"
First trial start
2026
Feb 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK139", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
- Moderate-to-Severe Atopic Dermatitis
- Chronic Spontaneous Urticaria
- Seasonal Allergic Rhinitis
- Prurigo Nodularis (PN)
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Chronic hives (urticaria) · Asthma · Allergies (allergic rhinitis) · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK139" as an intervention, largest first.
- A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous UrticariaPivotal-lookingNot yet recruiting
AkesoIndustry
NCT07875426 · 201 participants (planned) · Start Oct 21, 2026 · Primary completion Jan 8, 2029
Drug: AK139; Placebo · For: Chronic Spontaneous Urticaria
- A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic DermatitisPivotal-lookingNot yet recruiting
AkesoIndustry
NCT07502222 · 168 participants (planned) · Start Apr 7, 2026 · Primary completion Nov 2027
Drug: AK139 and placebo; AK139 and 5 more · For: Moderate-to-Severe Atopic Dermatitis
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With AsthmaPivotal-lookingNot yet recruiting
AkesoIndustry
NCT07436221 · 160 participants (planned) · Start Feb 28, 2026 · Primary completion Dec 27, 2026
Drug: AK139; AK139 and 2 more · For: Asthma
Sites: Guangzhou, China; Shanghai, China
- A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.Pivotal-lookingNot yet recruiting
AkesoIndustry
NCT07883213 · 132 participants (planned) · Start Oct 2026 · Primary completion Aug 2027
Drug: AK139; AK139 · For: Prurigo Nodularis (PN)
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic RhinitisPivotal-lookingNot yet recruiting
AkesoIndustry
NCT07436234 · 111 participants (planned) · Start Mar 2, 2026 · Primary completion Sep 30, 2026
Drug: AK139; AK139 and 1 more · For: Seasonal Allergic Rhinitis
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal PolypsNot yet recruiting
AkesoIndustry
NCT07755371 · 75 participants (planned) · Start Aug 10, 2026 · Primary completion Apr 30, 2027
Drug: AK139; Placebo · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Shanghai, China
- A Clinical Study of AK139 in Healthy SubjectsNot yet recruiting
AkesoIndustry
NCT06947109 · 48 participants (planned) · Start May 6, 2025 · Primary completion Jan 30, 2026
Drug: Placebo; AK111 · For: Healthy Subjects
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.